MetaVia Documenten
Documenten
67
Ticker
MTVA
ISIN
US64132R5037
MetaVia SEC Filings
MetaVia Documenten 2026
Deze pagina bevat alle officiële documenten en SEC-filings voor MetaVia aandelen (MTVA, ISIN: US64132R5037). Dit omvat jaarverslagen (Formulier 10-K), kwartaalrapporten (Formulier 10-Q) en insidertransacties (Formulier 4). Momenteel zijn 67 documenten beschikbaar. Gegevens worden regelmatig bijgewerkt om beleggers een volledig overzicht van MetaVia's regelgevingsfilings te bieden.
MetaVia Aandelenanalyse
MetaVia NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market.